Contingent consideration 1 - Summary of liabilities - contingent consideration (Detail) - AUD ($) |
Dec. 31, 2024 |
Jun. 30, 2024 |
Dec. 31, 2023 |
|---|---|---|---|
| Disclosure of contingent liabilities [line items] | |||
| Contingent consideration, current | $ 3,515,233 | $ 3,252,904 | |
| Contingent consideration, non-current | 3,288,664 | 3,751,717 | |
| Contingent consideration | 6,803,897 | 7,004,621 | $ 6,870,783 |
| Contingent consideration — Paxalisib [Member] | |||
| Disclosure of contingent liabilities [line items] | |||
| Contingent consideration, non-current | 1,354,155 | 1,265,654 | |
| Contingent consideration — EVT801 [Member] | |||
| Disclosure of contingent liabilities [line items] | |||
| Contingent consideration, current | 3,515,233 | 3,252,904 | |
| Contingent consideration, non-current | $ 1,934,509 | $ 2,486,063 |